Janux Therapeutics, Inc. (JANX)
Nasdaq · Healthcare · Biotechnology
$16.54−2.30%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.0B
- 52-week range
- $12.12 – $35.34
- 52-week change
- −25.39%
- EPS (trailing)
- −$1.64
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $10.0M (−5.55%)
- Net income
- −$114M
- Operating margin
- −1576.7%
- Diluted EPS
- −$1.83
- Free cash flow
- −$83.3M
From the company’s annual report on SEC EDGAR.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp.
Headquarters: San Diego, United States · 113 employees · januxrx.com